BeiGene Out-Licenses TIGIT Inhibitor to Novartis in $2.8 Billion Agreement
publication date: Dec 20, 2021
Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis oncology drugs in China outside of China's largest cities. BeiGene will receive a $300 million upfront payment, a $600-$700 million option payment within two years. $745 million in regulatory milestones and $1.15 billion in sales milestones, It will also receive royalties on sales. In January, Novartis in-licensed BeiGene's PD-1 candidate in a similar deal. Currently, BeiGene is testing the TIGIT inhibitor paired with the PD-1 in several global trials for NSCLC and other cancers. More details....
Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235) (NYSE: NVS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.